1. Scrip
  2. >>Rare Diseases

New CF Patient Subset For Vertex With Kaftrio's EU Approval

Opportunity Opens Following EU Approval Of Triple Combination

 
• By John Davis

EU approval came quicker than expected for Vertex’s new triple-combination CFTR drug, Kaftrio.   

Lungs
• Source: Shutterstock

A new subgroup of cystic fibrosis patients in the EU will be treatable with a CFTR modulator following the EU’s approval of Vertex Pharmaceuticals Incorporated.’s triple combination Kaftrio (ivacaftor/tezacaftor/elexacaftor).

Vertex estimates the market opportunity to be up to 10,000 patients in Europe – those 12 years or older with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 
• By Alaric DeArment

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

 
• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.